Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and cisplatin with radiotherapy for stage IIA–III cervical carcinoma
2006-003759-19Phase 2Terminated
- Sponsor
- University Hospital Örebro
- Start
- Nov 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and cisplatin in Cervical Cancer (CC), cervical squamous cell carcinoma (CSCC) and cervical adenocarcinoma, sponsored by University Hospital Örebro. Primary endpoint: Loco-regional tumor control at 4 months. Started Nov 2006; status: terminated.
02
Drugs
cetuximabcisplatin
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)cervical adenocarcinoma
Beyond the preview
Go deeper on 2006-003759-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003759-19.